Brenig Therapeutics

Brenig Therapeutics is a neurology-focused drug development company that utilizes an AI/ML-based discovery platform to create innovative therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead candidate, BT-267, is a small-molecule leucine-rich repeat kinase two (LRRK2) inhibitor designed to treat idiopathic and LRRK2-mutated Parkinson's disease. BT-267 is characterized by its efficient blood-brain barrier penetration, minimal peripheral exposure, and superior overall safety profile. The drug exhibits a best-in-class pharmacokinetic profile, enabling high and sustained brain exposure while minimizing on-target, off-tissue toxicity.

Preclinical data have demonstrated BT-267's high cerebrospinal fluid (CSF) to plasma ratio, in vivo efficacy in the brain, and the absence of visible lung and kidney morphological changes. The molecule also demonstrates remarkable selectivity, with 1,000x selectivity against other kinases and over 500x selectivity against other targets from the safety panel. The company announced plans for BT-267 to enter human clinical trials by the end of 2024.

Key customers and partnerships

Brenig Therapeutics has established a partnership with Expert Systems, a drug accelerator that has contributed to the development of multiple clinical candidates across various therapeutic areas. This collaboration supported Brenig's efforts in developing best-in-class LRRK2 inhibitors for the treatment of Parkinson's disease, including idiopathic cases. The partnership leveraged Expert Systems Accelerator's expertise in computer-aided drug design and structural biology to enhance Brenig's drug discovery process.